Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 3.2% - Time to Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shot up 3.2% during mid-day trading on Wednesday . The stock traded as high as $5.40 and last traded at $5.30. 10,276,902 shares changed hands during trading, a decline of 35% from the average session volume of 15,829,829 shares. The stock had previously closed at $5.13.

Analyst Ratings Changes

Several research firms have recently issued reports on RXRX. Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Monday, June 16th. Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $2.12 billion, a PE ratio of -2.94 and a beta of 0.91. The stock's 50 day moving average is $4.86 and its two-hundred day moving average is $6.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Brighton Jones LLC lifted its stake in Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares in the last quarter. Rhumbline Advisers raised its holdings in Recursion Pharmaceuticals by 7.6% in the 4th quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock valued at $2,258,000 after acquiring an additional 23,564 shares during the last quarter. Private Advisor Group LLC raised its holdings in Recursion Pharmaceuticals by 103.8% in the 4th quarter. Private Advisor Group LLC now owns 31,427 shares of the company's stock valued at $212,000 after acquiring an additional 16,008 shares during the last quarter. IFP Advisors Inc raised its holdings in Recursion Pharmaceuticals by 170.4% in the 4th quarter. IFP Advisors Inc now owns 11,831 shares of the company's stock valued at $80,000 after acquiring an additional 7,455 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $163,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.